Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 25593184)

  • 1. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
    Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; Suvà ML; Benes CH; Haber DA; Boussin FD; Zou L
    Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
    Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
    Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
    Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
    PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
    Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
    J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
    Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
    Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
    Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
    PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
    Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
    Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
    Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
    Temime-Smaali N; Guittat L; Wenner T; Bayart E; Douarre C; Gomez D; Giraud-Panis MJ; Londono-Vallejo A; Gilson E; Amor-Guéret M; Riou JF
    EMBO J; 2008 May; 27(10):1513-24. PubMed ID: 18418389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres.
    Pan X; Drosopoulos WC; Sethi L; Madireddy A; Schildkraut CL; Zhang D
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5940-E5949. PubMed ID: 28673972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Loss of
    Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
    Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
    Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
    PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere maintenance by telomerase and by recombination can coexist in human cells.
    Cerone MA; Londono-Vallejo JA; Bacchetti S
    Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells.
    Arora R; Lee Y; Wischnewski H; Brun CM; Schwarz T; Azzalin CM
    Nat Commun; 2014 Oct; 5():5220. PubMed ID: 25330849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus.
    Kamranvar SA; Chen X; Masucci MG
    Oncogene; 2013 Dec; 32(49):5522-30. PubMed ID: 23708666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
    Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
    Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
    de Nonneville A; Salas S; Bertucci F; Sobinoff AP; Adélaïde J; Guille A; Finetti P; Noble JR; Churikov D; Chaffanet M; Lavit E; Pickett HA; Bouvier C; Birnbaum D; Reddel RR; Géli V
    EMBO Mol Med; 2022 Oct; 14(10):e15859. PubMed ID: 35920001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
    Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
    Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening.
    Kim J; Sun C; Tran AD; Chin PJ; Ruiz PD; Wang K; Gibbons RJ; Gamble MJ; Liu Y; Oberdoerffer P
    Nat Struct Mol Biol; 2019 Mar; 26(3):213-219. PubMed ID: 30833786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.